RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, will be presenting data from the NeuVax™ (E75) Phase II adjuvant breast cancer clinical trial at the 2011 annual meeting of The American Society of Clinical Oncology (ASCO) in Chicago.

The presentation, entitled "Sequential administration of trastuzumab and a CD8 T-cell-eliciting HER2/neu peptide vaccine in patients with breast cancer compared to trastuzumab alone" (Abstract #564), will be presented at the poster session "Breast Cancer HER2/ER" on Monday, June 6^th from 1:00 - 5:00 PM CDT.

In addition, RXi will also be hosting a panel entitled "New Directions in Breast Cancer Therapeutics" on Sunday, June 5th, at 2:00 PM CDT at the Hyatt Regency McCormick Place. The panel presentation will include an update from the NeuVax Phase II clinical trial including the 36-month efficacy data, as well as Phase III plans. The 24 month landmark analysis was first presented at the ASCO Breast Cancer Meeting in October 2010.